TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
Stocks in this Quantisnow insightHealth Care
Historical context for TGTX
Across the 22 sessions after earlier TGTX headlines, the stock closed higher 17 times and lower 5 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TGTX | SPY |
|---|---|---|---|
| May 28, 2026 | TG Therapeutics to Participate in the Jefferies Global Healthcare Conference | -1.0% | +0.6% |
| May 27, 2026 | TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial | -1.3% | -0.0% |
| May 6, 2026 | TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance | +16.3% | +1.4% |
| Apr 30, 2026 | TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update | +0.6% | +1.0% |
| Apr 22, 2026 | TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting | +5.6% | +1.0% |
| Apr 15, 2026 | TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI | +0.1% | +0.8% |
Quantisnow market dataNASDAQ
TGTX
TG Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TGTX
Full TGTX profile on Quantisnow Follow TGTX and get a push notification the moment its next story breaks.